000155286 001__ 155286
000155286 005__ 20240320115509.0
000155286 0247_ $$2pmid$$apmid:33433030
000155286 0247_ $$2doi$$a10.1002/mds.28478
000155286 0247_ $$2ISSN$$a0885-3185
000155286 0247_ $$2ISSN$$a1531-8257
000155286 0247_ $$2altmetric$$aaltmetric:97546576
000155286 0247_ $$2pmid$$a33433030
000155286 037__ $$aDZNE-2021-00566
000155286 082__ $$a610
000155286 1001_ $$0P:(DE-2719)9001510$$aGrobe-Einsler, Marcus$$b0$$eFirst author$$udzne
000155286 245__ $$aDevelopment of SARA home , a New Video‐Based Tool for the Assessment of Ataxia at Home
000155286 260__ $$aNew York, NY$$bWiley$$c2021
000155286 3367_ $$2DRIVER$$aarticle
000155286 3367_ $$2DataCite$$aOutput Types/Journal article
000155286 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1681215579_16323
000155286 3367_ $$2BibTeX$$aARTICLE
000155286 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155286 3367_ $$00$$2EndNote$$aJournal Article
000155286 520__ $$aBackgroundClinical scales such as the Scale for the Assessment and Rating of Ataxia (SARA) cannot be used to study ataxia at home or to assess daily fluctuations. The objective of the current study was to develop a video-based instrument, SARAhome, for measuring ataxia severity easily and independently at home.MethodsBased on feasibility of self-application, we selected 5 SARA items (gait, stance, speech, nose-finger test, fast alternating hand movements) for SARAhome (range, 0–28). We compared SARAhome items with total SARA scores in 526 patients with spinocerebellar ataxia types 1, 2, 3, and 6 from the EUROSCA natural history study. To prospectively validate the SARAhome, we directly compared the self-applied SARAhome and the conventional SARA in 50 ataxia patients. To demonstrate feasibility of independent home recordings in a pilot study, 12 ataxia patients were instructed to obtain a video each morning and evening over a period of 14 days. All videos were rated offline by a trained rater.ResultsSARAhome extracted from the EUROSCA baseline data was highly correlated with conventional SARA (r = 0.9854, P < 0.0001). In the prospective validation study, the SARAhome was highly correlated with the conventional SARA (r = 0.9254, P < 0.0001). Five of 12 participants of the pilot study obtained a complete set of 28 evaluable videos. Seven participants obtained 13–27 videos. The intraindividual differences between the lowest and highest SARAhome scores ranged from 1 to 5.5.ConclusionThe SARAhome and the conventional SARA are highly correlated. Application at home is feasible. There was a considerable degree of intraindividual variability of the SARAhome scores.
000155286 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000155286 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000155286 650_2 $$2MeSH$$aAtaxia: diagnosis
000155286 650_2 $$2MeSH$$aCerebellar Ataxia
000155286 650_2 $$2MeSH$$aHumans
000155286 650_2 $$2MeSH$$aPilot Projects
000155286 650_2 $$2MeSH$$aProspective Studies
000155286 650_2 $$2MeSH$$aSeverity of Illness Index
000155286 650_2 $$2MeSH$$aSpinocerebellar Ataxias: diagnosis
000155286 693__ $$0EXP:(DE-2719)SCA-20140101$$5EXP:(DE-2719)SCA-20140101$$eRegistry for Spinocerebellar Ataxies$$x0
000155286 7001_ $$0P:(DE-2719)9000781$$aTaheri Amin, Arian$$b1
000155286 7001_ $$0P:(DE-2719)2811327$$aFaber, Jennifer$$b2
000155286 7001_ $$0P:(DE-2719)2812594$$aSchaprian, Tamara$$b3
000155286 7001_ $$0P:(DE-2719)2811564$$aJacobi, Heike$$b4
000155286 7001_ $$0P:(DE-HGF)0$$aSchmitz-Hübsch, Tanja$$b5
000155286 7001_ $$aDiallo, Alhassane$$b6
000155286 7001_ $$aTezenas du Montcel, Sophie$$b7
000155286 7001_ $$0P:(DE-2719)2810314$$aKlockgether, Thomas$$b8$$eLast author
000155286 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.28478$$gVol. 36, no. 5, p. 1242 - 1246$$n5$$p1242 - 1246$$tMovement disorders$$v36$$x1531-8257$$y2021
000155286 8564_ $$uhttps://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mds.28478
000155286 8564_ $$uhttps://pub.dzne.de/record/155286/files/7836.pdf$$yOpenAccess
000155286 8564_ $$uhttps://pub.dzne.de/record/155286/files/7836.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000155286 909CO $$ooai:pub.dzne.de:155286$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000155286 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001510$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000155286 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000781$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000155286 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811327$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000155286 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812594$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000155286 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811564$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000155286 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810314$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000155286 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000155286 9130_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000155286 9141_ $$y2021
000155286 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000155286 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000155286 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-11
000155286 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000155286 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-11
000155286 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2021$$d2022-11-11
000155286 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-30$$wger
000155286 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000155286 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000155286 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000155286 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-11
000155286 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2021$$d2022-11-11
000155286 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000155286 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000155286 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-11$$wger
000155286 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000155286 9201_ $$0I:(DE-2719)1011001$$kAG Klockgether$$lClinical Research Coordination$$x0
000155286 9201_ $$0I:(DE-2719)1011101$$kPatient studies, Bonn$$lPatient Studies$$x1
000155286 9201_ $$0I:(DE-2719)1011103$$kAG Spottke$$lClinical Trial Unit$$x2
000155286 980__ $$ajournal
000155286 980__ $$aVDB
000155286 980__ $$aUNRESTRICTED
000155286 980__ $$aI:(DE-2719)1011001
000155286 980__ $$aI:(DE-2719)1011101
000155286 980__ $$aI:(DE-2719)1011103
000155286 9801_ $$aFullTexts